Interestingly, the combined treatment of pemetrexed and anti-PD-L1 antibody synergistically amplified the numbers of both CD4+ and CD8+ TILs even more in the tumor surroundings (figure 3E), indicating that the immunosuppressive tumor microenvironment has been altered through this combinational treatment. This evidence concerns the gene CD4 and neoplasm.